Leiden Mutation: Difference between revisions
BillyBones (talk | contribs) (breakdown, link; typo; grammar) |
m (Corrections and treatment added) |
||
| Line 5: | Line 5: | ||
}} | }} | ||
[[File:0285fig2.gif|thumb|right|Guanine replaced by arginine.]] | [[File:0285fig2.gif|thumb|right|Guanine replaced by arginine.]] | ||
Leiden mutation is [[autosomal dominant]] hereditary mutation in gene for clotting [[factor V]]. Consequence of this mutation is [[blood clotting]] disturbance factor V is resistant | Leiden mutation is [[autosomal dominant]] hereditary mutation on chromosome 1 , in the gene for clotting [[factor V]]. Consequence of this mutation is a [[blood clotting]] disturbance. For blood coagulation we need factor Xa and factor V (co-factor) which activate thrombin the enzyme needed to cleave fibrinogen to fibrin to form the clot. Protein C acts as a regulator for the clotting. It does so by inhibiting in case of need factor V. By inhibiting factor V coagulation is halted since factor Xa cannot activate thrombin by it's self. In case of Laiden mutation of factor V , factor V is resistant to inhibition by [[Protein C]] (aPC resistance) which leads to thrombosis. | ||
Mutation is based on | Mutation is based on substitution of a single [[nucleotide]](position 1691, exon 10) which in turn leads to change of the amino acid sequence. Instead of Arginine the amino acid Glutamin is present in the polypeptide chain. | ||
Clinical manifestation is trombophilia with its complications: | Clinical manifestation is trombophilia with its complications: | ||
| Line 23: | Line 23: | ||
Diagnostic is based on [[RFLP]], [[PCR]] and DNA [[electrophoresis]]. | Diagnostic is based on [[RFLP]], [[PCR]] and DNA [[electrophoresis]]. | ||
<noinclude> | <noinclude> | ||
==Treatment== | |||
To prevent abortions in pregnant women low molecular heparins (Anti Xa) are prescribed daily subcutaneously until the end of the pregnancy. | |||
== Links == | == Links == | ||
=== Related Articles === | === Related Articles === | ||
Revision as of 23:40, 30 January 2013
| English: Leiden mutation, Factor V Leiden, Activated protein C resistance, APC resistance |  |
Leiden mutation is autosomal dominant hereditary mutation on chromosome 1 , in the gene for clotting factor V. Consequence of this mutation is a blood clotting disturbance. For blood coagulation we need factor Xa and factor V (co-factor) which activate thrombin the enzyme needed to cleave fibrinogen to fibrin to form the clot. Protein C acts as a regulator for the clotting. It does so by inhibiting in case of need factor V. By inhibiting factor V coagulation is halted since factor Xa cannot activate thrombin by it's self. In case of Laiden mutation of factor V , factor V is resistant to inhibition by Protein C (aPC resistance) which leads to thrombosis.
Mutation is based on substitution of a single nucleotide(position 1691, exon 10) which in turn leads to change of the amino acid sequence. Instead of Arginine the amino acid Glutamin is present in the polypeptide chain.
Clinical manifestation is trombophilia with its complications:
and higher risk of:
- abortions,
- premature childbirth.
Heterozygotes have 5-10 times higher risk of thrombosis than common population sample, homozygotes even 80-100 times higher risk. There is possible advantage of lower risk of massive bleeding after childbirth. The risk of trombophilia can be enhanced by using hormonal contraception in woman population, which is not recommended to use. Leiden mutation is the most often genetic disturbance of blood clotting, prevalence is 5% in European population. In the opposite side it is quite rare polymorphism in Asia and Africa.
Diagnostic is based on RFLP, PCR and DNA electrophoresis.
Treatment
To prevent abortions in pregnant women low molecular heparins (Anti Xa) are prescribed daily subcutaneously until the end of the pregnancy.
Links
Related Articles
Bibliography
- WikiSkripta.eu. Leidentská mutace [online]. ©2012. The last revision 2012-01-05, [cit. 2012-02-11]. <http://www.wikiskripta.eu/index.php/Leidensk%C3%A1_mutace>.
